Zions Bancorporation National Association UT Grows Stock Holdings in Repligen Corporation $RGEN

Zions Bancorporation National Association UT boosted its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 4.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,593 shares of the biotechnology company’s stock after purchasing an additional 672 shares during the period. Zions Bancorporation National Association UT’s holdings in Repligen were worth $1,939,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale raised its stake in Repligen by 1.0% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company’s stock valued at $961,000 after buying an additional 80 shares during the last quarter. Alliance Wealth Advisors LLC UT grew its holdings in shares of Repligen by 2.5% in the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company’s stock worth $468,000 after acquiring an additional 89 shares during the period. Drive Wealth Management LLC grew its holdings in shares of Repligen by 2.5% in the second quarter. Drive Wealth Management LLC now owns 3,796 shares of the biotechnology company’s stock worth $472,000 after acquiring an additional 93 shares during the period. State of Michigan Retirement System increased its position in Repligen by 0.8% during the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock valued at $1,585,000 after acquiring an additional 100 shares during the last quarter. Finally, Louisiana State Employees Retirement System lifted its holdings in Repligen by 0.7% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company’s stock valued at $1,858,000 after acquiring an additional 100 shares during the period. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a research note on Wednesday, October 1st. Weiss Ratings reissued a “sell (d)” rating on shares of Repligen in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $180.00 target price on shares of Repligen in a research report on Wednesday, September 3rd. Canaccord Genuity Group increased their price target on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Wednesday, October 29th. Finally, Barclays lifted their price target on shares of Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $173.85.

Repligen Stock Performance

RGEN opened at $142.82 on Monday. The firm has a market cap of $8.04 billion, a P/E ratio of 7,144.57, a PEG ratio of 3.32 and a beta of 1.15. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The company has a 50 day simple moving average of $137.92 and a two-hundred day simple moving average of $129.30. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The firm had revenue of $188.80 million for the quarter, compared to the consensus estimate of $181.23 million. During the same period last year, the firm earned $0.43 EPS. The company’s revenue was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Equities analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.